Cost–utility analysis of selective internal radiation therapy with Y-90 resin microspheres in hepatocellular carcinoma
Autor: | Damian Mullan, Rachel Evans, Paul Ross, Noemi Muszbek, Victoria K Brennan, Edit Remak, Fabien Colaone, Suki Shergill |
---|---|
Rok vydání: | 2021 |
Předmět: |
Oncology
Sorafenib Cancer Research medicine.medical_specialty Carcinoma Hepatocellular Cost effectiveness Cost-Benefit Analysis Brachytherapy law.invention 03 medical and health sciences 0302 clinical medicine Randomized controlled trial law Internal medicine medicine Humans Yttrium Radioisotopes health care economics and organizations Survival analysis Cost–utility analysis business.industry Patient Selection Liver Neoplasms Selective internal radiation therapy Health Care Costs General Medicine medicine.disease Survival Analysis Microspheres United Kingdom Tumor Burden Liver 030220 oncology & carcinogenesis Hepatocellular carcinoma Quality of Life 030211 gastroenterology & hepatology Quality-Adjusted Life Years Liver function business medicine.drug |
Zdroj: | Future Oncology. 17:1055-1068 |
ISSN: | 1744-8301 1479-6694 |
Popis: | Background: The study assessed the cost-utility of selective internal radiation therapy (SIRT) with Y-90 resin microspheres versus sorafenib in UK patients with unresectable hepatocellular carcinoma ineligible for transarterial chemoembolization. Materials & methods: A lifetime partitioned survival model was developed for patients with low tumor burden (≤25%) and good liver function (albumin–bilirubin grade 1). Efficacy, safety and quality of life data were from a European Phase III randomized controlled trial and published studies. Resource use was from registries and clinical surveys. Results: Discounted quality-adjusted life-years were 1.982 and 1.381, and discounted total costs were £29,143 and 30,927, for SIRT and sorafenib, respectively. Conclusion: SIRT has the potential to be a dominant (more efficacious/less costly) or cost-effective alternative to sorafenib in patients with unresectable hepatocellular carcinoma. |
Databáze: | OpenAIRE |
Externí odkaz: |